In a pan-cancer analysis including the TCGA-KIRC cohort, data showed an overall correlation between SETD2 deficiency, a more prominent immune activation signature, and higher tumor mutational burden (Lu et al., 2021). This evidence concerns the gene SETD2 and neoplasm.